Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Dianthus Therapeutics is focused on developing innovative autoimmune therapeutics with a strong pipeline aimed at patient-friendly self-administration methods [3]. Group 1: Product Development - The company is advancing two clinical-stage autoimmune therapeutics, emphasizing their best-in-class potential and infrequent subcutaneous self-administration [3]. - The first program, claseprubart, is a potent classical pathway inhibitor with an 8-week half-life, targeting activated C1s, and has shown positive Phase II results in Myasthenia Gravis (MG) [4]. - Clinical proof of concept has been established for classical pathway inhibition in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) [4]. - The product is designed for convenience, utilizing a single self-administered 300-milligram 2-milliliter auto-injector, with dosing every two or four weeks [4]. Group 2: Clinical Trials - The second program, DNTH212, has recently commenced its Phase I clinical trials [5].